<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (MDSs), also called <z:e sem="disease" ids="C0026986,C0033027" disease_type="Neoplastic Process" abbrv="">preleukemias</z:e>, are a group of myeloid hematopoietic malignant disorders </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the transformation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> into <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Leukemic transformation in 151 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was dynamically followed up </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical manifestation, peripheral blood and bone marrow condition, karyotypes, immunophenotypes, response to treatment, and prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolution from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were also observed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During the course of this study, over the past eight years and seven months, 21 (13.91%) of 151 MDS patients progressed to overt <z:hpo ids='HP_0001909'>leukemia</z:hpo>, with a median interval of 5 (1 - 23) months </plain></SENT>
<SENT sid="5" pm="."><plain>There were no significant differences between rates of leukemic transformation in comparison with the <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) patient groups </plain></SENT>
<SENT sid="6" pm="."><plain>Transformation occurred either gradually or rapidly </plain></SENT>
<SENT sid="7" pm="."><plain>There were five parameters positively correlated to leukemic transformation: under 40 years of age, <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> of 3 lineages, more than 15% blasts in the bone marrow, at least two abnormal karyotypes, and treatment with combined chemotherapy </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the 21 patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> suffered from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and most of them were M2, M4, or M5 </plain></SENT>
<SENT sid="9" pm="."><plain>Two (9.52%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients developed extramedullary infiltration </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0001882'>Leukopenia</z:hpo> was found in 47.62% of these patients </plain></SENT>
<SENT sid="11" pm="."><plain>Two thirds of these patients, whose bone marrows were generally hypercellular, suffered from <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>After developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 8 (47.06%) patients developed abnormal karyotypes </plain></SENT>
<SENT sid="13" pm="."><plain>High expression of immature myeloid antigens, including CD33 [(49.83 +/- 24.50)%], CD13 [(36.38 +/- 33.84)%], monocytic antigen CD14 [(38.50 +/- 24.60)%], and stem cell marker CD34 [(34.67 +/- 30.59)%], were found on bone marrow mononuclear cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients after leukemic transformation </plain></SENT>
<SENT sid="14" pm="."><plain>In some cases, lymphoid antigens, such as CD5, CD7, CD9, and CD19, coexisted with myeloid antigens </plain></SENT>
<SENT sid="15" pm="."><plain>A low complete remission rate (31.25%) and a short survival time, with median survival of 6 (1 - 28) months, were found in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated by induction chemotherapy </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> has a high risk of developing into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, either gradually or rapidly </plain></SENT>
<SENT sid="17" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> have specific biological characteristics and a worse prognosis </plain></SENT>
</text></document>